Physicochemical evaluation and non-isothermal kinetic study of the drug–excipient interaction between DOXEPIN (cas 1668-19-5) and lactose
-
Add time:09/27/2019 Source:sciencedirect.com
In this study, the incompatibility of DOXEPIN (cas 1668-19-5) in solid physical mixtures with lactose (monohydrate and anhydrous) was investigated. The compatibility testing was made using various physicochemical techniques, such as differential scanning calorimetry (DSC), Fourier-transform infrared (FTIR) spectroscopy, and mass spectrometry. Non-isothermally stressed physical mixtures were used to analyze the solid-state kinetic parameters. Data were fitted to different thermal models, such as Friedman, Flynn–Wall–Ozawa (FWO) and Kissinger–Akahira–Sunose (KAS) for different drug–excipient mixtures separately. Overall, the incompatibility of doxepin as a tertiary amine, with lactose as a reducing carbohydrate was successfully evaluated. DSC based kinetic analysis provided a simple and fast comparative data in different drug–excipient mixtures. It can be recommended to exclude lactose from doxepin's solid dosage formulations, and also to use the described procedure in the kinetic evaluation of drug–excipient incompatibility studies.
We also recommend Trading Suppliers and Manufacturers of DOXEPIN (cas 1668-19-5). Pls Click Website Link as below: cas 1668-19-5 suppliers
Prev:Clinical reviewDOXEPIN (cas 1668-19-5) for insomnia: A systematic review of randomized placebo-controlled trials
Next:Research paperAntidepressant polypharmacy and the potential of pharmacokinetic interactions: DOXEPIN (cas 1668-19-5) but not mirtazapine causes clinically relevant changes in venlafaxine metabolism) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Research paperAntidepressant polypharmacy and the potential of pharmacokinetic interactions: DOXEPIN (cas 1668-19-5) but not mirtazapine causes clinically relevant changes in venlafaxine metabolism10/01/2019
- Clinical reviewDOXEPIN (cas 1668-19-5) for insomnia: A systematic review of randomized placebo-controlled trials09/26/2019
- Original Research ArticleHighly sensitive LC–MS/MS method to estimate DOXEPIN (cas 1668-19-5) and its metabolite norDOXEPIN (cas 1668-19-5) in human plasma for a bioequivalence study09/25/2019
- Document headingTherapeutic rationale for low dose DOXEPIN (cas 1668-19-5) in insomnia patients09/24/2019
- Comparing DOXEPIN (cas 1668-19-5) cream to oral antihistamines for the treatment of itch in burn patients: A multi-center triple-blind randomized controlled trial09/10/2019